Success Metrics

Clinical Success Rate
92.9%

Based on 39 completed trials

Completion Rate
93%(39/42)
Active Trials
29(32%)
Results Posted
23%(9 trials)
Terminated
3(3%)

Phase Distribution

Ph early_phase_1
1
1%
Ph not_applicable
28
31%
Ph phase_1
9
10%
Ph phase_4
4
4%
Ph phase_2
16
18%
Ph phase_3
4
4%

Phase Distribution

10

Early Stage

16

Mid Stage

8

Late Stage

Phase Distribution62 total trials
Early Phase 1First-in-human
1(1.6%)
Phase 1Safety & dosage
9(14.5%)
Phase 2Efficacy & side effects
16(25.8%)
Phase 3Large-scale testing
4(6.5%)
Phase 4Post-market surveillance
4(6.5%)
N/ANon-phased studies
28(45.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.8%

39 of 46 finished

Non-Completion Rate

15.2%

7 ended early

Currently Active

29

trials recruiting

Total Trials

90

all time

Status Distribution
Active(34)
Completed(39)
Terminated(7)
Other(10)

Detailed Status

Completed39
Recruiting25
unknown10
Not yet recruiting5
Active, not recruiting4
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
90
Active
29
Success Rate
92.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.6%)
Phase 19 (14.5%)
Phase 216 (25.8%)
Phase 34 (6.5%)
Phase 44 (6.5%)
N/A28 (45.2%)

Trials by Status

active_not_recruiting44%
not_yet_recruiting56%
recruiting2528%
withdrawn44%
terminated33%
unknown1011%
completed3943%

Recent Activity

Clinical Trials (90)

Showing 20 of 90 trialsScroll for more
NCT05828082Phase 2

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

Active Not Recruiting
NCT04609046Phase 1

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Recruiting
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting
NCT01696994Not Applicable

Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)

Active Not Recruiting
NCT06803056Not Applicable

QUANTIFY: Quantitative Understanding of Advanced Novel Techniques for Imaging Fasciitis and Yielding Biomarkers

Completed
NCT06361498Not Applicable

Ultrasound for Evaluation of Percutaneous G-tube Position

Recruiting
NCT05549661Phase 1

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Recruiting
NCT01841723Phase 2

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Active Not Recruiting
NCT03492944

Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason

Completed
NCT05704283Early Phase 1

3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer

Recruiting
NCT07225114Phase 2

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Recruiting
NCT07621614Not Applicable

A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

Not Yet Recruiting
NCT00352534Phase 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

Completed
NCT07612293Not Applicable

STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection

Not Yet Recruiting
NCT07578116Phase 3

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

Not Yet Recruiting
NCT04329065Phase 2

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Recruiting
NCT05989828Phase 1

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Recruiting
NCT07203911Not Applicable

Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial

Recruiting
NCT06809972

Synovial Proliferation on Routine Ultrasound: Active or Inactive?

Recruiting
NCT06401330Phase 3

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
90